Table 3. Patients with liver-only disease within the First BEAT and NO16966 trials.

	All patients undergoing hepatic resection (%)	Curative-intent hepatic resections (%)	R0 hepatic resections (%)
First BEAT
All patients with liver-only disease n=704	132 (18.8%)	107 (15.2%)	85 (12.1%)
Patients receiving oxaliplatin-based chemotherapy n=350	85 (24.3%)	71 (20.3%)	54 (15.4%)
Patients receiving irinotecan-based chemotherapy n=230	43 (18.7%)	33 (14.3%)	27 (11.7%)
NO16966
XELOX or FOLFOX4 + bevacizumab n=211			26 (12.3)
XELOX or FOLFOX4 + placebo n=207			24 (11.6)

Abbreviations: BEAT=bevacizumab expanded access trial; FOLFOX4=5-FU and oxaliplatin; XELOX=capecitabine plus oxaliplatin.